OHSU

Cancer Program Share This OHSU Content

Doernbecher cancer program

Join the Knight Cancer Challenge!

Early detection is the gateway to a cancer-free world. Join our bold $1 billion campaign to end cancer as we know it.

We've changed the game before. We can do it again. OHSU’s own Dr. Brian Druker proved that a drug called Gleevec could shut down cancer cells without harming healthy ones. OHSU Doernbecher Children's Hospital was the first hospital to offer a clinical trial of Gleevec for children. Dr. Druker’s new goal is to find smarter, faster ways to detect and treat cancer before it becomes deadly.

The Knight Cancer Challenge. OHSU’s Knight Cancer Institute has launched an unprecedented $1 billion campaign to end cancer as we know it. Nike co-founder Phil Knight and his wife, Penny, have pledged to donate $500 million to support this ambitious line of research – if we can raise an additional $500 million in gifts and pledges in two years. Every gift supporting cancer research and care at Doernbecher counts toward the challenge.

How can you help? We need the support of everyone who cares about stopping cancer - individuals, families, community groups, corporations, government agencies and private foundations.

Help us reach our goal by making a gift to Doernbecher's pediatric cancer program today. 

 

watch our video

Watch our video to learn how we'll develop the next phase of cancer treatments, and what that means for cancer patients today.

 

About the Doernbecher cancer program

Doernbecher houses Oregon’s most comprehensive children’s cancer center, including an inpatient unit, outpatient clinic and infusion center. Advanced treatment programs in leukemia, neuro-oncology, stem cell transplantation, and developmental therapeutics ensure that children with cancer don’t have to leave Oregon to receive the most effective treatments.

With philanthropic investment, Doernbecher can serve more children, give hope to more families, and discover new ways to eradicate pediatric cancers.

Donate to pediatric cancer programs

make a gift

 

Questions?

If you have questions about giving, please contact the Doernbecher Foundation or learn about other Ways to Give.

Patient Stories

Katie

Katie was one of the first young patients to try the drug Gleevec to fight chronic myeloid leukemia (CML). Watch her video.

McKensi was three when she was diagnosed with leukemia.

Caleb's mom listened to her maternal instincts when her son noticed a bump on his wrist.

Why Doernbecher?

  • Doernbecher operates the only pedatric stem cell/bone marrow transplant program in the state
  • Doernbecher is one of only 21 hospitals in the country approved by the National Cancer Institute to participate in the COG  Phase I Consortium
  • Doernbecher's cancer program is ranked 19th in the nation by US News & World Report